Cargando…

The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal

BACKGROUND: Erenumab, a fully human monoclonal antibody directed against the calcitonin gene-related peptide receptor, was approved for the prevention of episodic (EM) or chronic migraine (CM) at the monthly dose of 70 mg or 140 mg. We reviewed the available literature to understand if patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ornello, Raffaele, Tiseo, Cindy, Frattale, Ilaria, Perrotta, Giulia, Marini, Carmine, Pistoia, Francesca, Sacco, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822439/ https://www.ncbi.nlm.nih.gov/pubmed/31666008 http://dx.doi.org/10.1186/s10194-019-1054-4

Ejemplares similares

Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
por: Ornello, Raffaele, et al.
Publicado: (2021)

Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data
por: Ornello, Raffaele, et al.
Publicado: (2020)

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
por: De Matteis, Eleonora, et al.
Publicado: (2022)

Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
por: Ornello, Raffaele, et al.
Publicado: (2020)

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
por: Ornello, Raffaele, et al.
Publicado: (2020)

Association between response to triptans and response to erenumab: real-life data
por: Frattale, Ilaria, et al.
Publicado: (2021)

Which is the best transcranial direct current stimulation protocol for migraine prevention? A systematic review and critical appraisal of randomized controlled trials
por: Ornello, Raffaele, et al.
Publicado: (2021)

Patterns of Migraine in Postmenopausal Women: A Systematic Review
por: Ornello, Raffaele, et al.
Publicado: (2021)

Behavioral and psychological factors in individuals with migraine without psychiatric comorbidities
por: Pistoia, Francesca, et al.
Publicado: (2022)

Migraine in menopausal women: a systematic review
por: Ripa, Patrizia, et al.
Publicado: (2015)

Migraine and body mass index categories: a systematic review and meta-analysis of observational studies
por: Ornello, Raffaele, et al.
Publicado: (2015)

Different effects of air microembolism through patent foramen ovale in patients with migraine: A quantitative electroencephalogram case series
por: Ornello, Raffaele, et al.
Publicado: (2022)

How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice
por: Tiseo, Cindy, et al.
Publicado: (2019)

Acute and Preventive Management of Migraine during Menstruation and Menopause
por: Ornello, Raffaele, et al.
Publicado: (2021)

O059. Predictors of response to botulinum toxin for the treatment of chronic migraine: data from a Headache Center
por: Ornello, Raffaele, et al.
Publicado: (2015)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

Symptoms of gait and coordination impairment in a patient with COVID-19 interstitial pneumonia
por: Pistoia, Francesca, et al.
Publicado: (2021)

Migraine and hemorrhagic stroke: data from general practice
por: Ornello, Raffaele, et al.
Publicado: (2015)

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India
por: Chowdhury, Debashish, et al.
Publicado: (2022)

O032. Associations between any headache and obesity: results from a systematic review and meta-analysis of observational studies
por: Degan, Diana, et al.
Publicado: (2015)

O050. Chronic daily headache and body mass index: a meta-analysis of observational studies
por: Tiseo, Cindy, et al.
Publicado: (2015)

European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention—part 2: flunarizine
por: Deligianni, Christina I., et al.
Publicado: (2023)

Peripheral vascular dysfunction in migraine: a review
por: Sacco, Simona, et al.
Publicado: (2013)

Serum CGRP in migraine patients using erenumab as preventive treatment
por: de Vries Lentsch, Simone, et al.
Publicado: (2022)

European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention—part 1: amitriptyline
por: Lampl, Christian, et al.
Publicado: (2023)

The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN)
por: Filippi, Massimo, et al.
Publicado: (2023)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
por: Belvís, Robert, et al.
Publicado: (2021)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
por: Ornello, Raffaele, et al.
Publicado: (2021)

A real‐world, observational study of erenumab for migraine prevention in Canadian patients
por: Becker, Werner J., et al.
Publicado: (2022)

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
por: Sakai, Fumihiko, et al.
Publicado: (2019)

Translation and Transcultural Adaptation of the Wessex Head Injury Matrix, Italian Version: A Preliminary Report
por: Pistoia, Francesca, et al.
Publicado: (2021)

Effectiveness of Transcranial Direct Current Stimulation and Monoclonal Antibodies Acting on the CGRP as a Combined Treatment for Migraine (TACTIC): Protocol for a Randomized, Double-Blind, Sham-Controlled Trial
por: Ornello, Raffaele, et al.
Publicado: (2022)

Optimal Dose of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Meta-Analysis
por: Yang, Yanbo, et al.
Publicado: (2022)

EHMTI-0392. Migraine and risk of ischemic heart disease: a systematic review and meta-analysis of observational studies
por: Sacco, S, et al.
Publicado: (2014)

Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study
por: Diener, Hans-Christoph, et al.
Publicado: (2021)

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Assessment and characteristics of Erenumab therapy on migraine management
por: Saeed, Haitham, et al.
Publicado: (2022)

Cranial autonomic symptoms and response to monoclonal antibodies targeting the Calcitonin gene-related peptide pathway: A real-world study
por: De Matteis, Eleonora, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7ff7ve3f1cp91gajhmjgleto6o